
This study identified for the first time SLAMF1 as a mediator of hepatocyte death in nonalcoholic fatty liver disease (NASH) and as a marker of NASH in humans. There are no pharmacological treatments available for NASH, and diagnostic tools are limited to invasive liver biopsies. Therefore, since SLAMF1 levels correlate with disease progression and SLAMF1 mediates cytotoxic effects, this protein can be used as a therapeutic target and a clinical biomarker of NASH.
Liver Cirrhosis, Mice, Liver, Signaling Lymphocytic Activation Molecule Family Member 1, Non-alcoholic Fatty Liver Disease, Signaling Lymphocytic Activation Molecule Family, Hepatocytes, Animals, Humans
Liver Cirrhosis, Mice, Liver, Signaling Lymphocytic Activation Molecule Family Member 1, Non-alcoholic Fatty Liver Disease, Signaling Lymphocytic Activation Molecule Family, Hepatocytes, Animals, Humans
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 8 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
